eTrueNorth’s ePOCT Suite™ of Solutions Now Used in Wal-Mart Stores, Inc.
/
Date30 Nov 2016
DALLAS, Nov. 30, 2016 (GLOBE NEWSWIRE) — eTrueNorth, the U.S.-based healthcare technology solution provider for CLIA-Waived laboratories, announced today that they have signed an agreement... Read More →
National Patient Safety Foundation Welcomes New Members to the Stand Up for Patient Safety Program
/
Date30 Nov 2016
BOSTON, Nov. 30, 2016 (GLOBE NEWSWIRE) — The National Patient Safety Foundation, a central voice for patient safety since 1997, recently welcomed five new organizations... Read More →
Cost of Care Conversations Are Not Taking Place Between Cancer Patients and Health Care Team
/
Date30 Nov 2016
WASHINGTON, Nov. 30, 2016 (GLOBE NEWSWIRE) — A study released today shows that despite the rising complexity and cost of cancer care, few patients are... Read More →
Diabetes in the United States: Gallup and Healthways Rank 50 States and 190 Communities
/
Date30 Nov 2016
WASHINGTON & NASHVILLE, Tenn., Nov. 30, 2016 (GLOBE NEWSWIRE) — World-leading analytics and advice firm Gallup, and global well-being improvement leader, Healthways, a Sharecare company, have released... Read More →
Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics
/
Date30 Nov 2016
SAN DIEGO and LONDON, Nov. 30, 2016 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. announced completion of its acquisition of drug development candidate, VRx-3996, from Chroma... Read More →
Apheresis Equipment Market size to exceed $4.5bn by 2024: Global Market Insights Inc.
/
Date30 Nov 2016
Ocean View, Delaware, Nov. 30, 2016 (GLOBE NEWSWIRE) — Apheresis Equipment Market size is set to exceed USD 4.5 billion by 2024; as per a... Read More →
Global HbA1c Testing Device Market expected to reach USD 2.20 Billion by 2021: Zion Market Research
/
Date30 Nov 2016
Sarasota, FL, Nov. 30, 2016 (GLOBE NEWSWIRE) — Zion Research has published a new report titled “Hba1c Testing Device Market by Device Type (Handheld Device... Read More →
Calithera Biosciences Reports CB-839 Phase I Renal Cell Carcinoma Combination Data at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
/
Date29 Nov 2016
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel... Read More →
Novo Nordisk A/S: Tresiba® viser en sikker kardiovaskulær profil og reducerer risikoen for alvorlig hypoglykæmi sammenlignet med insulin glargin U100 i DEVOTE-studiet
/
Date29 Nov 2016
Bagsværd, den 29. november 2016 – Novo Nordisk offentliggør i dag de overordnede resultater fra DEVOTE-studiet, et randomiseret, dobbeltblindet og hændelsesdrevet langtidsstudie, der er gennemført... Read More →
Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduces the risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial
/
Date29 Nov 2016
Bagsværd, 29 November 2016 – Today, Novo Nordisk announced the headline results from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to... Read More →